Anti-hCD20-Ga-hIgG1
Anti-hCD20-Ga-hIgG1 | Unit size | Cat. code | Docs | Qty | Price |
---|---|---|---|---|---|
Human CD20 (Obinutuzumab) antibody - Human IgG1 |
100 µg |
hcd20ga-mab1 |
You may also need : Anti-β-Gal-hIgG1 | View more associated products ▼
Monoclonal human IgG1 antibody against human CD20
Anti-hCD20-Ga-hIgG1 features a human IgG1 constant region (Fc) and the variable region of Obinutuzumab (formerly named Afutuzumab or GA101) which targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.
Obinutuzumab, is a type II (second generation) non-fucosylated, fully humanized IgG1 monoclonal antibody (mAb) with improved therapeutic efficacy compared to previously developed type I (first generation) anti-hCD20 mAbs, such as Rituximab and Ofatumumab. Obinutuzumab has been approved by the FDA for the treatment of chronic lymphocytic leukaemia (CLL) [1-3].
InvivoGen’s Anti-hCD20-Ga-hIgG1 is generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below).
InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Ofatumumab, with either native or engineered Fc regions.
Read our review on Antibody Isotypes
References:
1. Gagez AL. & Cartron G., 2014. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 26(5):484-91.
2. Smolej L., 2014. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med. 8:1-7.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.
Specifications
Target: Human CD20
Clonality: Monoclonal antibody
Source: CHO cells
Isotype: Human IgG1, kappa
Control: Human IgG1 control
Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose and stabilizing agents
Purity: Purified by affinity chromatography with protein G
Tested applications: Flow cytometry
Quality control:
- Binding of Anti-hCD20-Ga-hIgG1 to human CD20 has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Contents
- 100 µg purified Anti-hCD20-Ga-hIgG1 monoclonal antibody (mAb), provided azide-free and lyophilized
Anti-hCD20-Ga-hIgG1 is shipped at room temperature.
Store lyophilized antibody at -20 °C.